Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Does HER-2/neu antigen loss in metastatic breast tumors occur under immune pressure?

× No keyword cloud information.

7 in total

1. IFN-gamma can promote tumor evasion of the immune system in vivo by down-regulating cellular levels of an endogenous tumor antigen.

Authors: G L Beatty; Y Paterson
Journal: J Immunol Date: 2000-11-15 Impact factor: 5.422

2. HER-2/neu antigen loss and relapse of mammary carcinoma are actively induced by T cell-mediated anti-tumor immune responses.

Authors: Maciej Kmieciak; Keith L Knutson; Catherine I Dumur; Masoud H Manjili
Journal: Eur J Immunol Date: 2007-03 Impact factor: 5.532

3. Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion.

Authors: Brian J Czerniecki; Gary K Koski; Ursula Koldovsky; Shuwen Xu; Peter A Cohen; Rosemarie Mick; Harvey Nisenbaum; Terry Pasha; Min Xu; Kevin R Fox; Susan Weinstein; Susan G Orel; Robert Vonderheide; George Coukos; Angela DeMichele; Louis Araujo; Francis R Spitz; Mark Rosen; Bruce L Levine; Carl June; Paul J Zhang
Journal: Cancer Res Date: 2007-02-09 Impact factor: 12.701

4. Signatures associated with rejection or recurrence in HER-2/neu-positive mammary tumors.

Authors: Andrea Worschech; Maciej Kmieciak; Keith L Knutson; Harry D Bear; Aladar A Szalay; Ena Wang; Francesco M Marincola; Masoud H Manjili
Journal: Cancer Res Date: 2008-04-01 Impact factor: 12.701

5. HER-2/neu expression in primary and metastatic breast cancer.

Authors: Elyse E Lower; Eleanor Glass; Robbin Blau; Stacy Harman
Journal: Breast Cancer Res Treat Date: 2008-02-14 Impact factor: 4.872

6. Neu antigen-negative variants can be generated after neu-specific antibody therapy in neu transgenic mice.

Authors: Keith L Knutson; Bond Almand; Yushe Dang; Mary L Disis
Journal: Cancer Res Date: 2004-02-01 Impact factor: 12.701

7. HER-2 status discrepancy between primary breast cancer and metastatic sites. Impact on target therapy.

Authors: Alfredo Santinelli; Eleonora Pisa; Daniela Stramazzotti; Guidalberto Fabris
Journal: Int J Cancer Date: 2008-03-01 Impact factor: 7.396

7 in total

3 in total

1. Comparison of adjuvant activity of N- and C-terminal domain of gp96 in a Her2-positive breast cancer model.

Authors: Nafiseh Pakravan; Zuhair Mohammad Hassan
Journal: Cell Stress Chaperones Date: 2011-02-26 Impact factor: 3.667

2. Discordance in ER, PR, HER2, and Ki-67 Expression Between Primary and Recurrent/Metastatic Lesions in Patients with Primary Early Stage Breast Cancer and the Clinical Significance: Retrospective Analysis of 75 Cases.

Authors: Li Peng; Zhen Zhang; Dachun Zhao; Jialin Zhao; Feng Mao; Qiang Sun
Journal: Pathol Oncol Res Date: 2021-04-09 Impact factor: 3.201

3. IFN-γ Rα is a key determinant of CD8+ T cell-mediated tumor elimination or tumor escape and relapse in FVB mouse.

Authors: Maciej Kmieciak; Kyle K Payne; Xiang-Yang Wang; Masoud H Manjili
Journal: PLoS One Date: 2013-12-06 Impact factor: 3.240

3 in total